Beta-turn secondary structure and melanocortin ligands

Area of Science:

• Pharmacology and medicinal chemistry
• Endocrinology

Background:

• The melanocortin pathway is a key target for developing therapeutics for obesity and type 2 diabetes.
• This pathway involves peptide-ligand interactions with G-protein coupled receptors (GPCRs).
• Drug discovery has shifted from peptide-based ligands to small molecules with diverse scaffolds.

Purpose of the Study:

• To summarize the hypothesis linking reverse beta-turn secondary structure to melanocortin receptor agonist potency.
• To describe the utilization of this structural information in discovering small molecule agonists.

Main Methods:

• Review of existing research on melanocortin receptor ligands.
• Analysis of structure-activity relationships focusing on secondary structure.
• Identification and design of small molecules incorporating reverse beta-turn motifs.

Main Results:

• The reverse beta-turn secondary structure is critical for high agonist potency at melanocortin receptors.
• Small molecule scaffolds designed around this turn structure demonstrate significant potential.
• This approach has facilitated the development of novel therapeutic agents.

Conclusions:

• The reverse beta-turn hypothesis provides a valuable framework for designing potent melanocortin receptor agonists.
• Small molecule drug discovery targeting this pathway can be guided by specific structural insights.
• This strategy holds promise for advancing treatments for metabolic disorders like obesity and type 2 diabetes.